{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T14:03:41Z","timestamp":1787321021188,"version":"build-2736575974"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Austrian Science FundAustrian Science Fund (FWF)","award":["F4701-B20"],"award-info":[{"award-number":["F4701-B20"]}]},{"name":"Austrian Science FundAustrian Science Fund (FWF)","award":["F4704-B20"],"award-info":[{"award-number":["F4704-B20"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.leukres.2018.12.013","type":"journal-article","created":{"date-parts":[[2018,12,28]],"date-time":"2018-12-28T11:41:56Z","timestamp":1545997316000},"page":"36-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1T315I in Ph+ CML"],"prefix":"10.1016","volume":"78","author":[{"given":"Karoline V.","family":"Gleixner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Sadovnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Schneeweiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Eisenwort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Byrgazov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Stefanzl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emir","family":"Hadzijusufovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Valent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2018.12.013_bib0005","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2018.12.013_bib0010","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2018.12.013_bib0015","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2018.12.013_bib0020","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2018.12.013_bib0025","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.leukres.2018.12.013_bib0030","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2018.12.013_bib0035","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood.V99.9.3472","article-title":"High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR\/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance","volume":"99","author":"Branford","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.12.013_bib0040","first-page":"S11","article-title":"Resistance and relapse with imatinib in CML: causes and consequences","volume":"6","author":"Deininger","year":"2008","journal-title":"J. Compr. Canc. Netw."},{"key":"10.1016\/j.leukres.2018.12.013_bib0045","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1365-2141.2008.07197.x","article-title":"Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease","volume":"142","author":"Valent","year":"2008","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2018.12.013_bib0050","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.leukres.2018.12.013_bib0055","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2018.12.013_bib0060","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc2126","article-title":"Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia","volume":"7","author":"Weisberg","year":"2007","journal-title":"Nat. Rev. Cancer"},{"issue":"10","key":"10.1016\/j.leukres.2018.12.013_bib0065","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/j.1365-2362.2010.02328.x","article-title":"Standard treatment of Ph+ CML in 2010: how, when and where not to use what BCR\/ABL1 kinase inhibitor?","volume":"40","author":"Valent","year":"2010","journal-title":"Eur. J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.leukres.2018.12.013_bib0070","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.clml.2015.03.006","article-title":"Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm","volume":"15","author":"Jabbour","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.leukres.2018.12.013_bib0075","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nrclinonc.2016.139","article-title":"Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?","volume":"14","author":"Rosti","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.leukres.2018.12.013_bib0080","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/ajh.24247","article-title":"Chronic myeloid leukemia: second-line drugs of choice","volume":"91","author":"Gambacorti-Passerini","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2018.12.013_bib0085","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1182\/blood-2005-05-1932","article-title":"The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo","volume":"106","author":"Stover","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.12.013_bib0090","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","article-title":"Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets","volume":"110","author":"Rix","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.12.013_bib0095","doi-asserted-by":"crossref","first-page":"13283","DOI":"10.1073\/pnas.0702654104","article-title":"The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib","volume":"104","author":"Hantschel","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.leukres.2018.12.013_bib0100","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/leu.2008.334","article-title":"Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells","volume":"23","author":"Remsing Rix","year":"2009","journal-title":"Leukemia"},{"issue":"25","key":"10.1016\/j.leukres.2018.12.013_bib0105","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","article-title":"Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure","volume":"25","author":"Quint\u00e1s-Cardama","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2018.12.013_bib0110","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/ajh.22037","article-title":"Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML","volume":"86","author":"Aichberger","year":"2011","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2018.12.013_bib0115","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood-2014-09-594432","article-title":"Vascular safety issues in CML patients treated with BCR\/ABL1 kinase inhibitors","volume":"125","author":"Valent","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.12.013_bib0120","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.12.013_bib0125","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-09-0168","article-title":"Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors","volume":"8","author":"Grosso","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.leukres.2018.12.013_bib0130","doi-asserted-by":"crossref","first-page":"9809","DOI":"10.1158\/0008-5472.CAN-08-1008","article-title":"Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression","volume":"68","author":"Mahon","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.leukres.2018.12.013_bib0135","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/jnci\/djn188","article-title":"Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase","volume":"100","author":"Wu","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.leukres.2018.12.013_bib0140","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/leu.2008.364","article-title":"The stem cell factor-c-KIT pathway must be inhibited to enable apoptosis induced by BCR-ABL inhibitors in chronic myelogenous leukemia cells","volume":"23","author":"Belloc","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2018.12.013_bib0145","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.leukres.2010.06.030","article-title":"Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myelogenous leukemia patients","volume":"35","author":"Hayette","year":"2011","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2018.12.013_bib0150","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2007-11-123950","article-title":"Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy","volume":"112","author":"Jabbour","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.12.013_bib0155","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.1158\/1078-0432.CCR-08-0117","article-title":"Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia","volume":"14","author":"Quint\u00e1s-Cardama","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.leukres.2018.12.013_bib0160","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1182\/blood-2009-08-237115","article-title":"Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV","volume":"115","author":"Saussele","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2018.12.013_bib0165","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nrclinonc.2015.193","article-title":"Allogeneic transplantation for CML in the TKI era: striking the right balance","volume":"13","author":"Innes","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.leukres.2018.12.013_bib0170","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","article-title":"Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations","volume":"108","author":"Bradeen","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.12.013_bib0175","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1182\/blood-2006-06-026377","article-title":"Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias","volume":"109","author":"Weisberg","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.12.013_bib0180","doi-asserted-by":"crossref","first-page":"e4423","DOI":"10.1371\/journal.pone.0004423","article-title":"Combination of two but not three current targeted drugs can improve therapy of chronic myeloid leukemia","volume":"4","author":"Komarova","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.leukres.2018.12.013_bib0185","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1158\/0008-5472.CAN-09-2181","article-title":"Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536","volume":"70","author":"Gleixner","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.leukres.2018.12.013_bib0190","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ajh.24362","article-title":"Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia","volume":"91","author":"Gugliotta","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2018.12.013_bib0195","doi-asserted-by":"crossref","first-page":"23061","DOI":"10.18632\/oncotarget.15481","article-title":"TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML","volume":"8","author":"Valent","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.leukres.2018.12.013_bib0200","first-page":"375","article-title":"SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice","volume":"63","author":"Boschelli","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.leukres.2018.12.013_bib0205","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.ejca.2010.02.032","article-title":"Bosutinib: a review of preclinical studies in chronic myelogenous leukaemia","volume":"46","author":"Boschelli","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.leukres.2018.12.013_bib0210","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","article-title":"Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib","volume":"118","author":"Cortes","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.12.013_bib0215","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2011-11-390120","article-title":"Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and\/or nilotinib therapy failure","volume":"119","author":"Khoury","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.12.013_bib0220","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial","volume":"30","author":"Cortes","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2018.12.013_bib0225","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/bjh.13108","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial","volume":"168","author":"Br\u00fcmmendorf","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2018.12.013_bib0230","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/leu.2010.79","article-title":"Synergistic activity of the Src\/Abl inhibitor bosutinib in combination with imatinib","volume":"24","author":"Redaelli","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2018.12.013_bib0235","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1080\/1042819031000122033","article-title":"Aminopeptidase inhibitors inhibit proliferation and induce apoptosis of K562 and STI571-resistant K562 cell lines through the MAPK and GSK-3beta pathways","volume":"44","author":"Sawafuji","year":"2003","journal-title":"Leuk. Lymphoma"},{"issue":"7","key":"10.1016\/j.leukres.2018.12.013_bib0240","doi-asserted-by":"crossref","first-page":"5085","DOI":"10.1074\/jbc.M109.039206","article-title":"BCR-ABL gene expression is required for its mutations in a novel KCL22 cell culture model for acquired resistance of chronic myelogenous leukemia","volume":"285","author":"Yuan","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.leukres.2018.12.013_bib0245","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","article-title":"Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations","volume":"108","author":"Bradeen","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.12.013_bib0250","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.3324\/haematol.2016.163436","article-title":"Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia","volume":"102","author":"Gleixner","year":"2017","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.leukres.2018.12.013_bib0255","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/sj.leu.2404151","article-title":"The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib","volume":"20","author":"Miething","year":"2006","journal-title":"Leukemia"},{"issue":"16","key":"10.1016\/j.leukres.2018.12.013_bib0260","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.1128\/MCB.02202-05","article-title":"Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib","volume":"26","author":"Griswold","year":"2006","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.leukres.2018.12.013_bib0265","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/sj.leu.2404609","article-title":"Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies","volume":"21","author":"Jiang","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2018.12.013_bib0270","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction","volume":"107","author":"Copland","year":"2006","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261830506X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261830506X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,10]],"date-time":"2019-02-10T16:25:52Z","timestamp":1549815952000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521261830506X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":54,"alternative-id":["S014521261830506X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2018.12.013","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1T315I in Ph+ CML","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2018.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}